Please login to the form below

Not currently logged in
Email:
Password:

rituximab

This page shows the latest rituximab news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Sanofi’s all-oral sleeping sickness drug

CHMP backs Sanofi’s all-oral sleeping sickness drug

remission with minimal residual disease greater than or equal to 0.1%, and also backed Roche’s MabThera (rituximab) for adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis in

Latest news

More from news
Approximately 9 fully matching, plus 135 partially matching documents found.

Latest Intelligence

  • The sound of silence puts the squeeze on generics and biosimilars The sound of silence puts the squeeze on generics and biosimilars

    drugs - from Adalimumab to Rituximab - go off-patent and boost savings across eight European nations to 33.4bn over the next three years.

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab).

  • Deal Watch December 2016 Deal Watch December 2016

    Sanofi's payments to JHL, the Taiwanese manufacturer of a rituximab biosimilar, total $101m upfront for the China market alone; 30% of the headline figure.

  • Deal Watch November 2016 Deal Watch November 2016

    By destroying B cells, rituximab is used to treat diseases characterised by excessive numbers of B cells, overactive B cells or dysfunctional B cells including many lymphomas, leukaemias, transplant rejection and ... In May this year Sandoz announced

  • Deal Watch October 2016 Deal Watch October 2016

    Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    His previous business experience includes several oncology-related positions at Biogen Idec, including team leader for Rituxan (rituximab), as well as commercial positions at Amgen,.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics